Friday, February 15, 2013- GlaxoSmithKline and Pfizer's HIV Joint Venture Gets Priority Review for Dolutegravirat Motley Fool (Fri, Feb 15)
- Better Dividend: Merck or Pfizer?at Motley Fool (Fri, Feb 15)
- Today's Dow: Pops and Dropsat Motley Fool (Fri, Feb 15)
- The Dow's Dividend Winners in 2013at Motley Fool (Fri, Feb 15)
- Agilent Misses, Guidance DisappointsZacks (Fri, Feb 15)
- Wal-Mart’s UK Arm Discovers Horse DNA and 4 Dow Movers to Followat Wall St. Cheat Sheet (Fri, Feb 15)
- Dow's Bumpy Ride Keeps It in Positive Territoryat Motley Fool (Fri, Feb 15)
- 5 Stocks Pushing The Health Care Sector Higherat TheStreet (Fri, Feb 15)
- ViiV’s HIV Treatment Dolutegravir Will Get FDA Priority Reviewat Bloomberg (Fri, Feb 15)
- The Meat and Potatoes of Abbott Labsat Motley Fool (Fri, Feb 15)
- Dow Today: Pfizer (PFE) Leads The Day Higher, Wal-Mart Stores (WMT) Lagsat TheStreet (Fri, Feb 15)
- Pfizer Inc Stock Buy Recommendation Reiterated (PFE)at TheStreet (Fri, Feb 15)
- A Golden Opportunity in the Health Trends of Boomersat Motley Fool (Fri, Feb 15)
- 5 High-Yield Blue Chips To Buy With Solid Upside Potentialat Seeking Alpha (Fri, Feb 15)
- Zoetis - Successful Offering Fails To Lift Pfizer's Sharesat Seeking Alpha (Fri, Feb 15)
Thursday, February 14, 2013- A Pipeline Worth Buyingat Motley Fool (Thu, Feb 14)
- Ram Selvaraju: Fall In Love With These Biotech Stocksat Seeking Alpha (Thu, Feb 14)
- Will Pfizer Help You Retire Rich?at Motley Fool (Thu, Feb 14)
- Is Diversification Good or Bad?at Motley Fool (Thu, Feb 14)
- Which Company Will Rule This Multibillion-Dollar Market?at Motley Fool (Thu, Feb 14)
- Agilent Unit & Pfizer CollaborateZacks (Thu, Feb 14)
- The Next Stock You Should Considerat Motley Fool (Thu, Feb 14)
- Nestle makes $11.55 billion profit in 2012AP (Thu, Feb 14)
- Insurance Exchanges are On Track, Health Official Saysat Bloomberg (Thu, Feb 14)
- Hedge Fund Kahn Brothers’ Stock Picks for 2013at Motley Fool (Thu, Feb 14)
Add PFE News to My Yahoo!   | |
|
0.34%